[Diagnosis and therapy of neuroectodermal tumors]

Area of Science:

• Nuclear medicine
• Oncology
• Radiology

Context:

• Neuroectodermal neoplasms present diagnostic challenges.
• Accurate tumor detection is crucial for effective treatment planning.
• Evaluating imaging modalities for rare tumors is essential.

Purpose:

• To compare the accuracy of computed tomography (CT) and meta-iodo-benzyl-guanidine (MIBG) scintigraphy in detecting neuroectodermal tumors.
• To assess the efficacy of MIBG scintigraphy in identifying specific tumor types and manifestations.
• To evaluate the therapeutic application of 131I-MIBG in patients with surgically incurable neuroendocrine tumors.

Summary:

• MIBG scintigraphy demonstrated high sensitivity for pheochromocytomas (83%), neuroblastomas (100%), and carcinoids (71%), outperforming CT in detecting small adrenal pheochromocytomas and neuroblastoma bone metastases.
• CT showed higher sensitivity for pheochromocytomas (87%) and carcinoids (100%) but lower for neuroblastomas (77%).
• High-dose 131I-MIBG therapy was administered to eight patients with incurable tumors, resulting in complete remission in one patient with metastatic pheochromocytoma and partial remission in another.

Impact:

• MIBG scintigraphy is a valuable tool for diagnosing and staging neuroectodermal neoplasms, especially for small lesions and bone involvement.
• 131I-MIBG therapy shows promise as a treatment option for selected patients with advanced, surgically incurable neuroendocrine tumors.
• This study highlights the dual role of MIBG in diagnosis and therapy for neuroectodermal tumors.